Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL).
about
Drugs for rare disorders.Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs-a Systematic Literature Review. Next Steps in Methodology Development?The burden of common variable immunodeficiency disorders: a retrospective analysis of the European Society for Immunodeficiency (ESID) registry data
P2860
Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 March 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Recommendations from the Europ ...... s in Rare Diseases (ORPH-VAL).
@en
Recommendations from the Europ ...... ing Processes in Rare Diseases
@nl
type
label
Recommendations from the Europ ...... s in Rare Diseases (ORPH-VAL).
@en
Recommendations from the Europ ...... ing Processes in Rare Diseases
@nl
prefLabel
Recommendations from the Europ ...... s in Rare Diseases (ORPH-VAL).
@en
Recommendations from the Europ ...... ing Processes in Rare Diseases
@nl
P2093
P2860
P1476
Recommendations from the Europ ...... s in Rare Diseases (ORPH-VAL).
@en
P2093
Adam Hutchings
Carlo Tomino
David Taylor
Elena Nicod
Jean-Louis Roux
Josep Torrent-Farnell
Karen Facey
Lieven Annemans
Lugdivine Le Dez
Michael Schlander
P2860
P2888
P356
10.1186/S13023-017-0601-9
P577
2017-03-10T00:00:00Z
P6179
1084251816